4 completed, 1 active not recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow RSLV-132: new trials by email Literature Review of RSLV-132 trials Research Report on RSLV-132
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RSLV-132 in Females With Sjögren's Disease RSLV-132, Placebo - Primary Sjögren Syndrome | Phase 2 | Active not recruiting | Resolve Therapeutics | 106 | 2024-12-01 | 2026-10-16 |
| Phase 2 Study of RSLV-132 in Subjects With Long COVID RSLV-132, Sodium Chloride 0.9% - Post-acute Corona Virus 19 (COVID-19) (Long COVID) | Phase 2 | Completed | Resolve Therapeutics | 112 | 2021-06-25 | 2024-05-29 |
| A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome RSLV-132, Placebo - Sjogren's Syndrome | Phase 2 | Completed | Resolve Therapeutics | 28 | 2017-02-01 | 2021-04-02 |
| A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) RSLV-132, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | Resolve Therapeutics | 64 | 2016-01-03 | 2021-03-10 |
| Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus RSLV-132 - Systemic Lupus Erythematosus | Phase 1 | Completed | Resolve Therapeutics | 32 | 2014-07-01 | 2015-12-09 |
Lupus Erythematosus, Systemic (2) · COVID-19 (1) · Post-Acute COVID-19 Syndrome (1) · Sjogren's Syndrome (1)
United States (4) · United Kingdom (1)
James Posada, Ph.D. (3) · James Posada (2)